Dare Bioscience, Inc. 8-K

What Happened

• Daré Bioscience, Inc. (DARE) filed a Form 8-K on May 14, 2026 (Item 2.02) to announce its results of operations and financial condition for the quarter ended March 31, 2026. The company furnished a press release reporting those quarterly results as Exhibit 99.1 to the filing. The report is signed by Sabrina Martucci Johnson, President and Chief Executive Officer.

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02).
• Period covered: quarter ended March 31, 2026.
• Disclosure method: press release furnished as Exhibit 99.1.
• Authorized signature: Sabrina Martucci Johnson, President & CEO.

Why It Matters

• This 8-K notifies investors that Daré has released its latest quarterly results and that the details are available in the furnished press release. Investors should review Exhibit 99.1 and the company’s subsequent SEC filings (e.g., the quarterly report on Form 10-Q) for the full financial figures, revenue, earnings, and management commentary. The 8-K itself furnishes the news but does not replace complete periodic financial statements and footnotes.